The Benzinga Pro newswire reports shares of Mustang Bio Inc MBIO are trading higher after data was published in the New England Journal of Medicine on the company’s lentiviral gene therapy.
Benzinga Pro users were alerted to this news first when the data was shared.
MBIO released new data from a phase 1/2 clinical trial, where the company used lentiviral gene therapy on infants with X-linked Severe Combined Immunodeficiency, also known as “bubble boy disease.” The company will develop the therapy with St. Jude’s Children’s Research Hospital.
Shares of MBIO spiked more than 134 percent following the announcement.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
